Journal
EPIGENETICS
Volume 1, Issue 4, Pages 183-186Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/epi.1.4.3530
Keywords
gene methylation; biochemical recurrence; prostate cancer
Ask authors/readers for more resources
Up to 30% of men with clinically localized disease who receive radical prostatectomy develop a biochemical recurrence. Gene methylation in tumor tissue may distinguish men with aggressive cancer. This study evaluated methylation of GSTP1, RAR beta 2, CD44 and PTGS2 with biochemical recurrence among 60 patients who underwent radical prosta tectomy using logistic regression and Kaplan Meier time to event analysis. Methylation of GSTP1 and RAR beta 2 was not associated with recurrence, however, CD44 and PTGS2 methylation were significant predictors. In multivariate models adjusting for Gleason grade, the methylation profile of CD44 and PTGS2 combined was an independent predictor of biochemical recurrence (associated with 9-fold increased risk). In addition, Kaplan Meier analysis showed CD44 and PTGS2 methylation was associated with shorter time to recurrence. CD44 and PTGS2 methylation may predict biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and if validated in larger studies, may identify patients with aggressive cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available